DelNova, Inc. is a biopharmaceutical company focused on addressing unmet medical needs. DelNova is resolving complications arising from botulinum toxin therapies (eg. Botox®). The first product under development, ReViVox™ is based on a clinically validated drug currently approved for a different medical use and route of administration. The novel formulation will manage undesirable side effects resulting from neurotoxin injections in both medical and cosmetic applications.
Eyetamins is a healthcare technology and life sciences company focused on therapeutics and consumer innovations in the $200B eye health and wellness space. They...
In this episode, Ryan Khanna, MD, MBA co-hosts a discussion with Robert Eastlack who runs a premier surgical spine practice in San Diego, CA...
Jaffar Raza, MD is a board certified Interventional Cardiologist affiliated with Lenox Hill, Hackensack and Holy name hospitals. He completed his residency in Internal...
